Aurobindo Pharma to launch 19 products in US in next three quarters

06 Sep 2016 Evaluate

Aurobindo Pharma is planning to launch 19 approved products that have an addressable market of $6.8 billion in the US in the next three quarters. Moreover, the company has another 22 targeted ‘action dates through the end of the financial year’ although it does not ‘anticipate all those will be final approvals but a significant number will be’.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

Aurobindo Pharma Share Price

1224.75 14.85 (1.23%)
19-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1745.10
Dr. Reddys Lab 1278.90
Cipla 1517.00
Zydus Lifesciences 919.85
Lupin 2125.70
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×